Accretion Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a good return on equity (ROE) track record: 3 Years ROE 40.5%
- Company has a healthy return on capital (ROCE) of 29.6%
- Company comfortably covers its interest (16.0x coverage)
- Company maintains a comfortable, low leverage position
- Company converts assets efficiently - asset turnover of 1.5x
CONS
- Operating cash flow has been negative in recent years
- Receivables are growing faster than sales - a possible quality concern
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -1.49x)
- Free cash flow has been persistently negative
- Working capital days have increased from 65 to 161 days
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1904.00 | 37.77 | 456833.38 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9245.00 | 83.91 | 245425.70 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4924.70 | 85.89 | 187319.76 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1135.00 | 25.09 | 113216.68 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1389.00 | 33.29 | 112211.54 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1872.15 | 92.52 | 101154.55 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2135.00 | 17.66 | 97626.26 | 0.84 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2345.00 | 47.42 | 96859.07 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1155.00 | 29.92 | 96405.53 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1627.00 | 25.22 | 93613.98 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2458.80 | 38.60 | 69393.40 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ACCPL | 202.00 | 23.23 | 224.54 | 0.00 | — | — | — | — | 29.77 | — |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
No standalone quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 13 | 57 | 90 | |
| 11 | 45 | 75 | |
| Operating Profit | 3 | 12 | 15 |
| OPM % | 19.19% | 20.71% | 16.71% |
| 0 | 0 | 0 | |
| Interest | 0 | 1 | 1 |
| Depreciation | 0 | 1 | 1 |
| Profit before Tax | 2 | 10 | 13 |
| Tax % | 25.17% | 30.42% | 26.11% |
| Net Profit | 1 | 7 | 10 |
| EPS | 3.73 | 8.32 | 8.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 41%
- Last Year:
- 29%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4 | 8 | 11 |
| 1 | 7 | 44 | |
| 11 | 11 | 10 | |
| Trade Payables | 7 | 8 | 6 |
| 4 | 6 | 6 | |
| Total Liabilities | 27 | 40 | 77 |
| 5 | 6 | 13 | |
| 14 | 21 | 28 | |
| 6 | 12 | 22 | |
| Cash & Bank | 0 | 0 | 4 |
| 2 | 1 | 8 | |
| Total Assets | 27 | 40 | 77 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -12 | -1 | -15 | |
| Cash from Investing | -5 | -2 | -9 |
| Cash from Financing | 17 | 2 | 27 |
| 0 | -0 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| PER SHARE | |||
| EPS (₹) | 3.73 | 8.32 | 8.70 |
| Book Value (₹) | 13.73 | 18.59 | 46.91 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 2.26 | 9.26 | 9.79 |
| PROFITABILITY | |||
| Operating Margin % | 19.19% | 20.71% | 16.71% |
| Net Margin % | 11.18% | 11.84% | 10.79% |
| ROE % | 27.18% | 65.71% | 28.72% |
| ROCE % | 12.62% | 46.42% | 29.77% |
| 5.44% | 20.18% | 16.59% | |
| EFFICIENCY | |||
| Debtor Days | 159 | 56 | 69 |
| Inventory Days | 396 | 112 | 100 |
| Payable Days | 256 | 65 | 37 |
| 298 | 102 | 132 | |
| FINANCIAL HEALTH | |||
| Debt to Equity (x) | 2.45x | 0.93x | 0.24x |
| Interest Coverage (x) | 6.00x | 7.79x | 16.03x |
| 1.47x | 1.44x | 2.90x | |
| GROWTH | |||
| Revenue Growth % | 0.00% | 329.70% | 56.21% |
| Operating Profit Growth % | 0.00% | 357.51% | 26.62% |
| Net Profit Growth % | 0.00% | 355.08% | 42.31% |
| 0.00% | 122.81% | 4.59% | |
| VALUATION | |||
| P/E (x) | 0.00x | 0.00x | 7.31x |
| P/B (x) | 0.00x | 0.00x | 1.35x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% |
| 6.64x | 1.86x | 5.21x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for ACCPL
Loading news…
AI Stock Analyst
Accretion Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account